Transcenta Holding Limited stock analysis
Want to see HK:6628 full AI Analyst Report?
Transcenta Holding Limited (6628) Stock Price & Analysis
6628 Stock Chart & Stats
- Day’s Range
- HKD 0.62 - HKD 0.68
- 52-Week Range
- HKD 0.55 - HKD 3.06
- Previous Close
- HKD 0.63
- Volume
- N/A
- Average Volume (3M)
- 766.03K
- Market Cap
- HKD 280.79M
- Enterprise Value
- HKD 657.83M
- Total Cash (Recent Filing)
- HKD 3.50M
- Total Debt (Recent Filing)
- HKD 137.79M
- Price to Earnings (P/E)
- ―
- Beta
- 1.71
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Integrated Biopharma Capabilities
Operating across discovery, clinical development, manufacturing, and commercialization gives Transcenta an integrated biopharma platform. This can support control over product development and production while also enabling use of its capabilities for its own pipeline and external work.
Improving Leverage
Lower debt-to-equity indicates reduced reliance on borrowings and provides a stronger balance-sheet position than in prior years. Although the capital base is weakening, improving leverage can preserve financial flexibility and reduce borrowing-related pressure over the medium term.
Reduced Cash Burn
The reduction in operating cash outflow suggests progress in managing cash consumption, even though cash generation remains negative. If sustained, lower burn could extend financial flexibility and reduce the pace at which external funding is needed to support operations.
Bears Say
Revenue Contraction
Material revenue contraction points to weak commercial scale and limits the company’s ability to spread research, development, and operating costs across a larger business. Continued lower revenue can constrain reinvestment capacity and delay the path toward sustainable profitability.
Persistent Unprofitability
Negative gross profit indicates that product or service economics are currently insufficient even before operating expenses are considered. Persistent operating and net losses reduce internal funding capacity, weaken operating leverage, and make future profitability dependent on substantial improvement.
Ongoing Cash Consumption
Consistently negative operating and free cash flow means the business is not yet funding its activities internally. Continued cash consumption can increase reliance on external capital, constrain strategic investment, and heighten financing pressure if losses persist.
Transcenta Holding Limited News
Transcenta Advances Licensing and Funding Drive to Ease Liquidity and Address Audit Disclaimer
Transcenta Holding Limited ( ($HK:6628) ) has provided an announcement. Transcenta Holding Limited said it is pressing ahead with nine measures to ease liquidity pressures and strengthen its balance sheet,
Transcenta Bolsters Claudin18.2 IP With New China Patent Backing Global Osemitamab Push
Transcenta Holding Limited ( ($HK:6628) ) has provided an announcement. Transcenta Holding Limited has strengthened its intellectual property portfolio around its flagship Claudin18.2-targeting program, osemitamab (TST001), with a new China
Transcenta Adds Independent Director, Restores Compliance and Grants Share Award
Transcenta Holding Limited ( ($HK:6628) ) just unveiled an announcement. Transcenta Holding Limited has appointed renowned microbiology and immunology expert Prof. Genhong Cheng as an independent non-executive director, effective August
6628 FAQ
What was Transcenta Holding Limited’s price range in the past 12 months?
What is Transcenta Holding Limited’s market cap?
When is Transcenta Holding Limited’s upcoming earnings report date?
How were Transcenta Holding Limited’s earnings last quarter?
Is Transcenta Holding Limited overvalued?
Does Transcenta Holding Limited pay dividends?
What is Transcenta Holding Limited’s EPS estimate?
How many shares outstanding does Transcenta Holding Limited have?
What happened to Transcenta Holding Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Transcenta Holding Limited?
What is the TipRanks Smart Score and how is it calculated?
Transcenta Holding Limited Stock Smart Score
Company Description
Transcenta Holding Limited
Transcenta Holding Limited is a clinical-stage biopharmaceutical company focused on the discovery, research, development, manufacturing, and commercialization of therapeutic agents within the People's Republic of China and the United States. The company boasts a comprehensive pipeline of drug candidates. In oncology, its key developments include: MSB2311, a humanized PD-L1 monoclonal antibody, currently in Phase Ib/IIa trials for various solid tumors, particularly those with high tumor mutational burden (TMB-H). TST001, a humanized claudin 18.2 monoclonal antibody undergoing Phase II clinical development for solid tumors, such as gastric cancer. TST005, a bifunctional PD-L1/TGF-ß antibody in Phase Ia clinical trials for solid tumors, including certain types of lung cancer. TST010, an antibody designed to target regulatory T cells, aiming to bolster T cell-mediated anti-tumor activity. TST003, an antibody addressing a novel immune regulatory protein produced by tumor-associated fibroblasts or tumor cells exhibiting a mesenchymal phenotype. TST006, a bispecific antibody targeting both claudin 18.2 and PD-L1. TST008, a trifunctional antibody that combines a MASP2 antibody with a truncated transmembrane activator and CAML interactor protein. MSB0254, a humanized VEGFR-2 monoclonal antibody also in Phase Ib/IIa clinical studies for solid tumors. Beyond cancer, Transcenta is advancing: TST002 (Blosozumab), a humanized sclerostin monoclonal antibody for the treatment of osteoporosis. TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) monoclonal antibody intended for IgA kidney diseases. The company has forged collaboration agreements with prominent organizations, including Eli Lilly and Company, Alebund Pharmaceuticals, and Merck. Founded in 2010 as MabSpace International Limited, the entity adopted the name Transcenta Holding Limited in June 2019. Its corporate headquarters are located in Suzhou, People's Republic of China.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Xueming Qian
- Employees
- 150
- Website
- www.transcenta.com
- Address
- B6-501, 218 Xinghu Street, Suzhou, JS, 215123, CN
Transcenta Holding Limited (6628) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 14 |
| Technical Analysis | 2 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |










